Idogen has announces that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company.

“It has been a privilege to lead Idogen for the past three years and I am convinced that the company’s competent board and employees will continue to deliver significant progress for the benefit of large patient groups as well as the shareholders,” says Anders Karlsson, resigning CEO of Idogen.

He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.

“I am looking forward to being operationally involved in the advancement of the IDO 8 program in these exciting times, as we soon will be starting our Phase I/IIa study in the Nordic region,” says Christina Herder, incoming CEO of Idogen.

Photo of Anders Karlsson: Idogen